Skye Bioscience, Inc.
NASDAQ: SKYE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Punit Dhillon
- Employees
- 12
- Headquarters
- San Diego, United States
- IPO year
- 2015
- Market cap
- $23.9M
- Website
- https://skyebioscience.com
Loading SKYE…
Loading profile data…Frequently asked questions about SKYE
What does Skye Bioscience, Inc. (SKYE) do?
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key G...
Where does SKYE trade?
Skye Bioscience, Inc. (SKYE) trades on the NASDAQ.
What sector is SKYE in?
Skye Bioscience, Inc. (SKYE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Skye Bioscience, Inc.?
Punit Dhillon is the chief executive officer of Skye Bioscience, Inc. (SKYE).
Where is Skye Bioscience, Inc. headquartered?
Skye Bioscience, Inc. is headquartered in United States.
Does SKYE pay a dividend?
Skye Bioscience, Inc. (SKYE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SKYE go public?
Skye Bioscience, Inc. (SKYE) completed its initial public offering in 2015.